Bay City Capital Llc - Net Worth and Insider Trading

Bay City Capital Llc Net Worth

The estimated net worth of Bay City Capital Llc is at least $40 Million dollars as of 2024-05-06. Bay City Capital Llc is the 10% Owner of Madrigal Pharmaceuticals Inc and owns about 124,255 shares of Madrigal Pharmaceuticals Inc (MDGL) stock worth over $29 Million. Bay City Capital Llc is the 10% Owner of Epizyme Inc and owns about 5,654,532 shares of Epizyme Inc (EPZM) stock worth over $8 Million. Bay City Capital Llc is also the 10% Owner of Xilio Therapeutics Inc and owns about 1,129,490 shares of Xilio Therapeutics Inc (XLO) stock worth over $1 Million. Besides these, Bay City Capital Llc also holds Kezar Life Sciences Inc (KZR) , Nevro Corp (NVRO) , Dermira Inc (DERM) , Sunesis Pharmaceuticals Inc (SNSS) . Details can be seen in Bay City Capital Llc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Bay City Capital Llc has not made any transactions after 2021-10-26 and currently still holds the listed stock(s).

Transaction Summary of Bay City Capital Llc

Bay City Capital Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Bay City Capital Llc owns 14 companies in total, including Madrigal Pharmaceuticals Inc (MDGL) , Imara Inc (IMRA) , and Kezar Life Sciences Inc (KZR) among others .

Click here to see the complete history of Bay City Capital Llc’s form 4 insider trades.

Insider Ownership Summary of Bay City Capital Llc

Ticker	Comapny	Transaction Date	Type of Owner
MDGL	Madrigal Pharmaceuticals Inc	2020-08-19	10 percent owner
IMRA	Imara Inc	2020-03-11	10 percent owner
KZR	Kezar Life Sciences Inc	2018-06-25	10 percent owner
		2016-07-29	10 percent owner
		2014-08-26	10 percent owner
		2015-07-24	10 percent owner
		2015-06-08	10 percent owner
		2014-10-08	director & 10 percent owner
		2011-09-23	10 percent owner
		2010-11-15	10 percent owner
		2007-08-30	10 percent owner
		2015-07-24	10 percent owner
		2021-10-26	10 percent owner
		2020-03-11	10 percent owner

Bay City Capital Llc Latest Holdings Summary

Bay City Capital Llc currently owns a total of 7 stocks. Among these stocks, Bay City Capital Llc owns 124,255 shares of Madrigal Pharmaceuticals Inc (MDGL) as of August 19, 2020, with a value of $29 Million and a weighting of 71.93%. Bay City Capital Llc owns 5,654,532 shares of Epizyme Inc (EPZM) as of August 26, 2014, with a value of $8 Million and a weighting of 20.74%. Bay City Capital Llc also owns 1,129,490 shares of Xilio Therapeutics Inc (XLO) as of October 26, 2021, with a value of $1 Million and a weighting of 3.49%. The other 4 stocks Kezar Life Sciences Inc (KZR) , Nevro Corp (NVRO) , Dermira Inc (DERM) , Sunesis Pharmaceuticals Inc (SNSS) have a combined weighting of 3.83% among all his current holdings.

Latest Holdings of Bay City Capital Llc

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
MDGL	Madrigal Pharmaceuticals Inc	2020-08-19	124,255	232.00	28,826,539
EPZM	Epizyme Inc	2014-08-26	5,654,532	1.47	8,312,162
XLO	Xilio Therapeutics Inc	2021-10-26	1,129,490	1.24	1,400,568
KZR	Kezar Life Sciences Inc	2018-06-25	622,229	0.84	524,477
NVRO	Nevro Corp	2015-06-08	36,403	11.09	403,709
DERM	Dermira Inc	2014-10-02	17,240	18.75	323,250
SNSS	Sunesis Pharmaceuticals Inc	2015-07-24	53,468	5.32	284,450

Holding Weightings of Bay City Capital Llc

Bay City Capital Llc Form 4 Trading Tracker

According to the SEC Form 4 filings, Bay City Capital Llc has made a total of 2 transactions in Madrigal Pharmaceuticals Inc (MDGL) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Madrigal Pharmaceuticals Inc is the sale of 30,000 shares on August 19, 2020, which brought Bay City Capital Llc around $3 Million.

According to the SEC Form 4 filings, Bay City Capital Llc has made a total of 0 transactions in Epizyme Inc (EPZM) over the past 5 years. The most-recent trade in Epizyme Inc is the sale of 200,000 shares on August 26, 2014, which brought Bay City Capital Llc around $7 Million.

According to the SEC Form 4 filings, Bay City Capital Llc has made a total of 1 transactions in Xilio Therapeutics Inc (XLO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Xilio Therapeutics Inc is the acquisition of 312,500 shares on October 26, 2021, which cost Bay City Capital Llc around $5 Million.

More details on Bay City Capital Llc's insider transactions can be found in the Insider Trading History of Bay City Capital Llc table.

Insider Trading History of Bay City Capital Llc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Bay City Capital Llc Trading Performance

GuruFocus tracks the stock performance after each of Bay City Capital Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Bay City Capital Llc is 6.57%. GuruFocus also compares Bay City Capital Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Bay City Capital Llc within 3 months outperforms 2 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Bay City Capital Llc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Bay City Capital Llc

Average Return

Average return per transaction

Outperforming Transactions

0 out of 3 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	10.81
Relative Return to S&P 500(%)	8.61

Bay City Capital Llc Ownership Network

Ownership Network List of Bay City Capital Llc

No Data

Ownership Network Relation of Bay City Capital Llc

Bay City Capital Llc Owned Company Details

What does Madrigal Pharmaceuticals Inc do?

Who are the key executives at Madrigal Pharmaceuticals Inc?

Bay City Capital Llc is the 10 percent owner of Madrigal Pharmaceuticals Inc. Other key executives at Madrigal Pharmaceuticals Inc include director & Chief Executive Officer Paul A Friedman , director & Chief Medical Officer & EVP R&D Rebecca Taub , and Senior VP & Chief Pharma Dev. Robert E. Waltermire .

Madrigal Pharmaceuticals Inc (MDGL) Insider Trades Summary

Over the past 18 months, Bay City Capital Llc made no insider transaction in Madrigal Pharmaceuticals Inc (MDGL). Other recent insider transactions involving Madrigal Pharmaceuticals Inc (MDGL) include a net purchase of 424,685 shares made by Baker Bros. Advisors Lp , a net sale of 29,800 shares made by Brian Joseph Lynch , and a net sale of 100,000 shares made by Paul A Friedman .

In summary, during the past 3 months, insiders sold 252,542 shares of Madrigal Pharmaceuticals Inc (MDGL) in total and bought 0 shares, with a net sale of 252,542 shares. During the past 18 months, 342,631 shares of Madrigal Pharmaceuticals Inc (MDGL) were sold and 424,685 shares were bought by its insiders, resulting in a net purchase of 82,054 shares.

Madrigal Pharmaceuticals Inc (MDGL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Madrigal Pharmaceuticals Inc Insider Transactions

No Available Data

What does Imara Inc do?

Who are the key executives at Imara Inc?

Bay City Capital Llc is the 10 percent owner of Imara Inc. Other key executives at Imara Inc include director & President & CEO Rahul D. Ballal , See Remarks Michael Gray , and 10 percent owner Braden Michael Leonard .

Imara Inc (IMRA) Insider Trades Summary

Over the past 18 months, Bay City Capital Llc made no insider transaction in Imara Inc (IMRA). Other recent insider transactions involving Imara Inc (IMRA) include a net sale of 2,590,000 shares made by Braden Michael Leonard , a net purchase of 29,899 shares made by Ra Capital Healthcare Fund Lp , and a net sale of 11,313 shares made by Rahul D. Ballal .

In summary, during the past 3 months, insiders sold 0 shares of Imara Inc (IMRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,604,909 shares of Imara Inc (IMRA) were sold and 29,899 shares were bought by its insiders, resulting in a net sale of 2,575,010 shares.

Imara Inc (IMRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Imara Inc Insider Transactions

No Available Data

What does Kezar Life Sciences Inc do?

Who are the key executives at Kezar Life Sciences Inc?

Bay City Capital Llc is the 10 percent owner of Kezar Life Sciences Inc. Other key executives at Kezar Life Sciences Inc include 10 percent owner Morningside Venture Investments Ltd , Chief Business Officer Nicholas Michael Mordwinkin , and 10 percent owner Equal Talent Investments Ltd .

Kezar Life Sciences Inc (KZR) Insider Trades Summary

Over the past 18 months, Bay City Capital Llc made no insider transaction in Kezar Life Sciences Inc (KZR). Other recent insider transactions involving Kezar Life Sciences Inc (KZR) include a net sale of 508,747 shares made by Morningside Venture Investments Ltd ,

In summary, during the past 3 months, insiders sold 0 shares of Kezar Life Sciences Inc (KZR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 508,747 shares of Kezar Life Sciences Inc (KZR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 508,747 shares.

Kezar Life Sciences Inc (KZR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kezar Life Sciences Inc Insider Transactions

No Available Data

What does Interleukin Genetics Inc do?

Who are the key executives at Interleukin Genetics Inc?

Bay City Capital Llc is the 10 percent owner of Interleukin Genetics Inc. Other key executives at Interleukin Genetics Inc include 10 percent owner Patrick J Kerins , 10 percent owner Growth Equity Opportunities Fund III, LLC , and Interim CFO Stephen J. Dipalma .

Interleukin Genetics Inc (ILIU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Interleukin Genetics Inc (ILIU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Interleukin Genetics Inc (ILIU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Interleukin Genetics Inc (ILIU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Interleukin Genetics Inc Insider Transactions

No Available Data

What does Epizyme Inc do?

Who are the key executives at Epizyme Inc?

Bay City Capital Llc is the 10 percent owner of Epizyme Inc. Other key executives at Epizyme Inc include Chief Scientific Officer Jeffery Kutok , Chief Operating Officer Jerald Korn , and Corporate Controller Joseph Beaulieu .

Epizyme Inc (EPZM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Epizyme Inc (EPZM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Epizyme Inc (EPZM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Epizyme Inc (EPZM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Epizyme Inc Insider Transactions

No Available Data

What does Sunesis Pharmaceuticals Inc do?

Who are the key executives at Sunesis Pharmaceuticals Inc?

Bay City Capital Llc is the 10 percent owner of Sunesis Pharmaceuticals Inc. Other key executives at Sunesis Pharmaceuticals Inc include director & See Remarks Dayton Misfeldt , VP & Finance Tina Gullotta , and See Remarks William P. Quinn .

Sunesis Pharmaceuticals Inc (SNSS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sunesis Pharmaceuticals Inc (SNSS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sunesis Pharmaceuticals Inc (SNSS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sunesis Pharmaceuticals Inc (SNSS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sunesis Pharmaceuticals Inc Insider Transactions

No Available Data

What does Nevro Corp do?

Who are the key executives at Nevro Corp?

Bay City Capital Llc is the 10 percent owner of Nevro Corp. Other key executives at Nevro Corp include Chief Commercial Officer Greg Siller , President & CEO Kevin R Thornal , and Chief Accounting Officer Richard B. Carter .

Nevro Corp (NVRO) Insider Trades Summary

Over the past 18 months, Bay City Capital Llc made no insider transaction in Nevro Corp (NVRO). Other recent insider transactions involving Nevro Corp (NVRO) include a net purchase of 7,500 shares made by Shawn Mccormick ,

In summary, during the past 3 months, insiders sold 0 shares of Nevro Corp (NVRO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Nevro Corp (NVRO) were sold and 7,500 shares were bought by its insiders, resulting in a net purchase of 7,500 shares.

Nevro Corp (NVRO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Nevro Corp Insider Transactions

No Available Data

What does Dermira Inc do?

Who are the key executives at Dermira Inc?

Bay City Capital Llc is the director & 10 percent owner of Dermira Inc. Other key executives at Dermira Inc include director & CEO & Chairman of the Board Thomas G Wiggans , CFO Andrew Guggenhime , and Chief Commercial Officer Lori Lyons-williams .

Dermira Inc (DERM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Dermira Inc (DERM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dermira Inc (DERM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Dermira Inc (DERM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dermira Inc Insider Transactions

No Available Data

What does Reshape Lifesciences Inc do?

Who are the key executives at Reshape Lifesciences Inc?

Bay City Capital Llc is the 10 percent owner of Reshape Lifesciences Inc. Other key executives at Reshape Lifesciences Inc include Chief Financial Officer Thomas Stankovich , President and CEO Barton P. Bandy , and director & Chairman & President and CEO Dan W Gladney .

Reshape Lifesciences Inc (RSLS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Reshape Lifesciences Inc (RSLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Reshape Lifesciences Inc (RSLS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Reshape Lifesciences Inc (RSLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Reshape Lifesciences Inc Insider Transactions

No Available Data

What does VIA Pharmaceuticals Inc do?

Who are the key executives at VIA Pharmaceuticals Inc?

Bay City Capital Llc is the 10 percent owner of VIA Pharmaceuticals Inc. Other key executives at VIA Pharmaceuticals Inc include 10 percent owner Bay City Capital Fund Iv Co Invesment Fund Lp , 10 percent owner Bay City Capital Management Iv Llc , and 10 percent owner Bay City Capital Fund Iv, L.p. .

VIA Pharmaceuticals Inc (VIAP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of VIA Pharmaceuticals Inc (VIAP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of VIA Pharmaceuticals Inc (VIAP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

VIA Pharmaceuticals Inc (VIAP)'s detailed insider trading history can be found in Insider Trading Tracker table.

VIA Pharmaceuticals Inc Insider Transactions

No Available Data

What does Poniard Pharmaceuticals Inc do?

Who are the key executives at Poniard Pharmaceuticals Inc?

Bay City Capital Llc is the 10 percent owner of Poniard Pharmaceuticals Inc. Other key executives at Poniard Pharmaceuticals Inc include President & CMO Michael S Perry , director & Chief Executive Officer Ron Martell , and director & 10 percent owner Simon Nicholas J Iii .

Poniard Pharmaceuticals Inc (PARD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Poniard Pharmaceuticals Inc (PARD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Poniard Pharmaceuticals Inc (PARD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Poniard Pharmaceuticals Inc (PARD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Poniard Pharmaceuticals Inc Insider Transactions

No Available Data

What does Viracta Therapeutics Inc do?

Who are the key executives at Viracta Therapeutics Inc?

Bay City Capital Llc is the 10 percent owner of Viracta Therapeutics Inc. Other key executives at Viracta Therapeutics Inc include Chief Executive Officer Daniel R. Chevallard , director & President and CEO Mark Rothera , and Chief Medical Officer Darrel P. Cohen .

Viracta Therapeutics Inc (VIRX) Insider Trades Summary

Over the past 18 months, Bay City Capital Llc made no insider transaction in Viracta Therapeutics Inc (VIRX). Other recent insider transactions involving Viracta Therapeutics Inc (VIRX) include a net sale of 21,403 shares made by Daniel R. Chevallard , a net sale of 4,272 shares made by Lisa Rojkjaer , and a net purchase of 100,000 shares made by Mark Rothera .

In summary, during the past 3 months, insiders sold 3,405 shares of Viracta Therapeutics Inc (VIRX) in total and bought 0 shares, with a net sale of 3,405 shares. During the past 18 months, 25,675 shares of Viracta Therapeutics Inc (VIRX) were sold and 100,000 shares were bought by its insiders, resulting in a net purchase of 74,325 shares.

Viracta Therapeutics Inc (VIRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viracta Therapeutics Inc Insider Transactions

No Available Data

What does Xilio Therapeutics Inc do?

Who are the key executives at Xilio Therapeutics Inc?

Bay City Capital Llc is the 10 percent owner of Xilio Therapeutics Inc. Other key executives at Xilio Therapeutics Inc include 10 percent owner Atlas Venture Fund Xi, L.p. , Chief Medical Officer Katarina Luptakova , and Chief Operating Officer Christopher James Frankenfield .

Xilio Therapeutics Inc (XLO) Insider Trades Summary

Over the past 18 months, Bay City Capital Llc made no insider transaction in Xilio Therapeutics Inc (XLO). Other recent insider transactions involving Xilio Therapeutics Inc (XLO) include a net sale of 5,235 shares made by Atlas Venture Fund Xi, L.p. , and a net purchase of 485,250 shares made by Gilead Sciences Inc .

In summary, during the past 3 months, insiders sold 1,000 shares of Xilio Therapeutics Inc (XLO) in total and bought 485,250 shares, with a net purchase of 484,250 shares. During the past 18 months, 5,235 shares of Xilio Therapeutics Inc (XLO) were sold and 485,250 shares were bought by its insiders, resulting in a net purchase of 480,015 shares.

Xilio Therapeutics Inc (XLO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Xilio Therapeutics Inc Insider Transactions

No Available Data

What does Enliven Therapeutics Inc do?

Who are the key executives at Enliven Therapeutics Inc?

Bay City Capital Llc is the 10 percent owner of Enliven Therapeutics Inc. Other key executives at Enliven Therapeutics Inc include director & Chief Scientific Officer Joseph P Lyssikatos , Chief Financial Officer Benjamin Hohl , and director & President and CEO Samuel Kintz .

Enliven Therapeutics Inc (ELVN) Insider Trades Summary

Over the past 18 months, Bay City Capital Llc made no insider transaction in Enliven Therapeutics Inc (ELVN). Other recent insider transactions involving Enliven Therapeutics Inc (ELVN) include a net sale of 143,709 shares made by Samuel Kintz , a net sale of 126,000 shares made by Joseph P Lyssikatos , and a net sale of 51,625 shares made by Anish Patel .

In summary, during the past 3 months, insiders sold 1,142,213 shares of Enliven Therapeutics Inc (ELVN) in total and bought 0 shares, with a net sale of 1,142,213 shares. During the past 18 months, 2,446,104 shares of Enliven Therapeutics Inc (ELVN) were sold and 622 shares were bought by its insiders, resulting in a net sale of 2,445,482 shares.

Enliven Therapeutics Inc (ELVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Enliven Therapeutics Inc Insider Transactions

No Available Data

Bay City Capital Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Bay City Capital Llc. You might contact Bay City Capital Llc via mailing address: 750 Battery Street Ste 400, San Francisco Ca 94111.

Discussions on Bay City Capital Llc

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.